McKesson (NYSE:MCK) Releases FY 2026 Earnings Guidance

Key Points

• McKesson has updated its FY 2026 earnings guidance, projecting earnings per share (EPS) of $38.050-$38.550, exceeding the consensus estimate of $37.370.
• Research analysts have raised their price targets for McKesson, with increases from firms like JPMorgan, Mizuho, and TD Cowen, resulting in an average target price of $829.08.
• The company recently declared a quarterly dividend of $0.82 per share, up from the previous $0.71, reflecting a commitment to returning value to shareholders.

McKesson (NYSE:MCK - Get Free Report) updated its FY 2026 earnings guidance on Sunday. The company provided earnings per share (EPS) guidance of 38.050-38.550 for the period, compared to the consensus estimate of 37.370. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of research analysts recently weighed in on MCK shares. JPMorgan Chase & Co. lifted their target price on McKesson from $821.00 to $853.00 and gave the company an "overweight" rating in a report on Friday, September 26th. Mizuho lifted their price objective on McKesson from $750.00 to $770.00 and gave the company a "neutral" rating in a research note on Wednesday, September 24th. TD Cowen boosted their target price on McKesson from $830.00 to $864.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. Weiss Ratings restated a "buy (b)" rating on shares of McKesson in a report on Saturday, September 27th. Finally, Leerink Partners lifted their price target on shares of McKesson from $785.00 to $850.00 and gave the company an "outperform" rating in a research report on Wednesday, September 24th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $829.08.

McKesson Stock Performance

Shares of NYSE:MCK opened at $738.00 on Friday. The business's 50-day simple moving average is $702.60 and its 200 day simple moving average is $703.23. The company has a market cap of $91.79 billion, a P/E ratio of 29.43, a PEG ratio of 1.32 and a beta of 0.52. McKesson has a one year low of $480.39 and a one year high of $776.14.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $8.26 earnings per share for the quarter, missing analysts' consensus estimates of $8.33 by ($0.07). The company had revenue of $97.83 billion during the quarter, compared to analysts' expectations of $95.93 billion. McKesson had a negative return on equity of 196.66% and a net margin of 0.84%.The firm's revenue was up 23.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $7.88 EPS. Analysts predict that McKesson will post 32.77 earnings per share for the current year.

McKesson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 1st. Investors of record on Tuesday, September 2nd were paid a dividend of $0.82 per share. This is a positive change from McKesson's previous quarterly dividend of $0.71. The ex-dividend date of this dividend was Tuesday, September 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson's payout ratio is presently 13.08%.

Insiders Place Their Bets

In other McKesson news, CEO Brian S. Tyler sold 19,371 shares of the company's stock in a transaction dated Friday, July 11th. The shares were sold at an average price of $708.09, for a total value of $13,716,411.39. Following the completion of the transaction, the chief executive officer directly owned 27,872 shares of the company's stock, valued at $19,735,884.48. This represents a 41.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $663.67, for a total value of $218,347.43. Following the sale, the chief accounting officer owned 657 shares of the company's stock, valued at $436,031.19. This represents a 33.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,560 shares of company stock worth $30,438,602 in the last quarter. 0.08% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On McKesson

A number of institutional investors have recently made changes to their positions in the business. Brighton Jones LLC increased its stake in shares of McKesson by 46.3% in the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company's stock worth $1,438,000 after buying an additional 798 shares during the last quarter. Caxton Associates LLP acquired a new position in McKesson during the 1st quarter worth $233,000. Sivia Capital Partners LLC increased its position in shares of McKesson by 77.9% in the 2nd quarter. Sivia Capital Partners LLC now owns 685 shares of the company's stock worth $502,000 after purchasing an additional 300 shares during the last quarter. Treasurer of the State of North Carolina raised its stake in shares of McKesson by 0.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company's stock valued at $42,958,000 after purchasing an additional 508 shares in the last quarter. Finally, Osterweis Capital Management Inc. bought a new position in shares of McKesson during the second quarter worth about $166,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.